Immunotherapy of brain cancers: The past, the present, and future directions

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Jadus, Martin R ^a,c,d   Ge, Lisheng ^a   Hoa, Neil ^a   Bota, Daniela A ^b   Natividad, Josephine ^a   Howat, Andrew ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; DENDRITIC CELL VACCINE; HEAT SHOCK PROTEIN; IMMUNOLOGICAL ADJUVANT; IPILIMUMAB; NIMOTUZUMAB; PEPTIDE VACCINE; RAMUCIRUMAB; RILOTUMUMAB; TENASCIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BRAIN CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; CELL LYSATE; GAMMA DELTA T LYMPHOCYTE; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HELPER CELL; HUMAN; IMMUNE RESPONSE; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; VACCINATION; ANIMAL; BRAIN TUMOR; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 79955080612     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/296453     Document Type: Review

References (179)

1. Doolittle N. D., Abrey L. E., Bleyer W. A., Brem S., Davis T. P., Dore-Duffy P., Drewes L. R., Hall W. A., Hoffman J. M., Korfel A., Martuza R., Muldoon L. L., Peereboom D., Peterson D. R., Rabkin S. D., Smith Q., Stevens G. H. J., Neuwelt E. A., New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the 10th annual blood-brain barrier disruption consortium meeting Clinical Cancer Research 2005 11 2 421 428 (Pubitemid 40116864)
2. Walker P. R., Calzascia T., Dietrich P. Y., All in the head: obstacles for immune rejection of brain tumours Immunology 2002 107 1 28 38
3. Carson M. J., Sutcliffe J. G., Campbell I. L., Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation Journal of Neuroscience Research 1999 55 1 127 134 (Pubitemid 29014418)
4. Aloisi F., Ria F., Penna G., Adorini L., Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation Journal of Immunology 1998 160 10 4671 4680 (Pubitemid 28215299)
5. Karman J., Ling C., Sandor M., Fabry Z., Initiation of immune responses in brain is promoted by local dendritic cells Journal of Immunology 2004 173 4 2353 2361 (Pubitemid 39063091)
6. Choi C., Park J. Y., Lee J., Lim J. H., Shin E. C., Ahn Y. S., Kim C. H., Kim SE. J., Kim J. D., Choi IL. S., Choi IN. H., Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-, or IFN- Journal of Immunology 1999 162 4 1889 1895 (Pubitemid 29288802)
7. Pelton R. W., Saxena B., Jones M., Moses H. L., Gold L. I., Immunohistochemical localization of TGF 1, TGF 2, and TGF 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development Journal of Cell Biology 1991 115 4 1091 1105 (Pubitemid 21909956)
8. Janeway C. A., Approaching the asymptote? Evolution and revolution in immunology Cold Spring Harbor Symposia on Quantitative Biology 1989 54 1 1 13
9. Cookson M. S., Herr H. W., Zhang Z. F., Soloway S., Sogani P. C., Fair W. R., The treated natural history of high risk superficial bladder cancer: 15-year outcome Journal of Urology 1997 158 1 62 67 (Pubitemid 27251595)
10. Wikstrand C. J., Bigner D. D., Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction Journal of Neuroimmunology 1981 1 3 249 260 (Pubitemid 11024451)
11. Albright L., Seab J. A., Ommaya A. K., Intracerebral delayed hypersensitivity reactions in glioblastoma multiforme patients Cancer 1977 39 3 1331 1336 (Pubitemid 8076157)
12. Gallucci S., Lolkema M., Matzinger P., Natural adjuvants: endogenous activators of dendritic cells Nature Medicine 1999 5 11 1249 1255 (Pubitemid 29535601)
13. Srivastava P., Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses Annual Review of Immunology 2002 20 395 425 (Pubitemid 34293430)
14. Suto R., Srivastava P. K., A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides Science 1995 269 5230 1585 1588
15. Binder R. J., Blachere N. E., Srivastava P. K., Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules Journal of Biological Chemistry 2001 276 20 17163 17171
16. Graner M. W., Cumming R. I., Bigner D. D., The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences Journal of Neuroscience 2007 27 42 11214 11227 (Pubitemid 47621325)
17. Graner M. W., Alzate O., Dechkovskaia A. M., Keene J. D., Sampson J. H., Mitchell D. A., Bigner D. D., Proteomic and immunologic analyses of brain tumor exosomes FASEB Journal 2009 23 5 1541 1557
18. Graner M. W., Raynes D. A., Bigner D. D., Guerriero V., Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces Cancer Science 2009 100 10 1870 1879
19. Basu S., Binder R. J., Ramalingam T., Srivastava P. K., CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin Immunity 2001 14 3 303 313 (Pubitemid 32289294)
20. Basu S., Binder R. J., Suto R., Anderson K. M., Srivastava P. K., Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF- B pathway International Immunology 2000 12 11 1539 1546
21. Kuppner M. C., Gastpar R., Gelwer S., Nssner E., Ochmann O., Scharner A., Issels R. D., The role of heat shock protein (hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors European Journal of Immunology 2001 31 5 1602 1609 (Pubitemid 32454709)
22. Asea A., Kraeft S. K., Kurt-Jones E. A., Stevenson M. A., Chen L. B., Finberg R. W., Koo G. C., Calderwood S. K., HSP70 stimulates cytokine production through a CD 14-dependant pathway, demonstrating its dual role as a chaperone and cytokine Nature Medicine 2000 6 4 435 442 (Pubitemid 30208161)
23. Parsa A. T., Aghi M., Ahn B., Bruce J., Butkowski N., Autologous heat shock protein vaccine for patients with newly diagnosed and recurrent glioblastoma Proceedings of the 18th International Conference on Brain Tumor Research and Therapy 2010. Abstract 9-2
24. Glick R. P., Lichtor T., Kim T. S., Ilangovan S., Cohen E. P., Martuza R. L., Rutka J. T., Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo Neurosurgery 1995 36 3 548 555
25. Tzeng J. J., Barth R. F., Clendenon N. R., Gordon W. A., Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2 Cancer Research 1990 50 14 4338 4343 (Pubitemid 20225675)
26. Rosenberg S. A., Lotze M. T., Muul L. M., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone New England Journal of Medicine 1987 316 15 889 897 (Pubitemid 17041979)
27. Hayes R. L., Koslow M., Hiesiger E. M., Hymes K. B., Hochster H. S., Moore E. J., Pierz D. M., Chen D. K., Budzilovich G. N., Ransohoff J., Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma Cancer 1995 76 5 840 852
28. Huang Y., Hayes R. L., Wertheim S., Arbit E., Scheff R., Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report Critical Reviews in Oncology/Hematology 2001 39 1-2 17 23 (Pubitemid 32564866)
29. Dillman R. O., Duma C. M., Schiltz P. M., DePriest C., Ellis R. A., Okamoto K., Beutel L. D., De Leon C., Chico S., Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma Journal of Immunotherapy 2004 27 5 398 404 (Pubitemid 39121929)
30. Dillman R. O., Duma C. M., Ellis R. A., Cornforth A. N., Schiltz P. M., Sharp S. L., Depriest M. C., Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma Journal of Immunotherapy 2009 32 9 914 919
31. Fujimiya Y., Suzuki Y., Katakura R., Miyagi T., Yamaguchi T., Yoshimoto T., Ebina T., In vitro interleukin 12 activation of peripheral blood CD3 CD56 and CD3 CD56 T cells from glioblastoma patients Clinical Cancer Research 1997 3 4 633 643
32. Friese M. A., Platten M., Lutz S. Z., Naumann U., Aulwurm S., Bischof F., Bhring H. J., Dichgans J., Rammensee H. G., Steinle A., Weller M., MICA/NKG2D-mediated immunogene therapy of experimental gliomas Cancer Research 2003 63 24 8996 9006 (Pubitemid 38064081)
33. Bryant N. L., Gillespie G. Y., Lopez R. D., Markert J. M., Cloud G. A., Langford C. P., Arnouk H., Su Y., Haines H. L., Suarez-Cuervo C., Lamb L. S., Preclinical evaluation of ex vivo expanded/activated T cells for immunotherapy of glioblastoma multiforme Journal of Neuro-Oncology 2010 101 2 179 188
34. Lamb L. S., T cells as immune effectors against high-grade gliomas Immunologic Research 2009 45 1 85 95
35. Bryant N. L., Suarez-Cuervo C., Gillespie G. Y., Markert J. M., Nabors L. B., Meleth S., Lopez R. D., Lamb L. S., Characterization and immunotherapeutic potential of T-cells in patients with glioblastoma Neuro-Oncology 2009 11 4 357 367
36. Tjuvajev J., Gansbacher B., Desai R., Beattie B., Kaplitt M., Matei C., Koutcher J., Gilboa E., Blasberg R., RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon- Cancer Research 1995 55 9 1902 1910
37. Visse E., Siesj P., Widegren B., Sjgren H. O., Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-, interleukin-7, or B7-1-transfected tumor cells Cancer Gene Therapy 1999 6 1 37 44 (Pubitemid 129667757)
38. Graf M. R., Jadus M. R., Hiserodt J. C., Wepsic H. T., Granger G. A., Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor Journal of Immunology 1999 163 10 5544 5551
39. Sanchez R., Williams C., Daza J. L., Dan Q., Xu Q., Chen Y., Delgado C., Arpajirakul N., Jeffes E. W. B., Kim R. C., Douglass T., Al Atar U., Terry Wepsic H., Jadus M. R., T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas Cellular Immunology 2002 215 1 1 11
40. Chen Y., Douglass T., Jeffes E. W.B., Xu Q., Williams C. C., Arpajirakul N., Delgado C., Kleinman M., Sanchez R., Dan Q., Kim R. C., Terry Wepsic H., Jadus M. R., Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"- induced pathway that promotes systemic immunity against intracranial T9 gliomas Blood 2002 100 4 1373 1380 (Pubitemid 34864294)
41. Jeffes E. W. B., Zhang J. G., Hoa N., Petkar A., Delgado C., Chong S., Obenaus A., Sanchez R., Khalaghizadeh S., Khomenko T., Knight B. A., Alipanah R., Nguyen T. V., Shah C., Vohra S., Zhuang J. L., Liu J., Wepsic H. T., Jadus M. R., Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma Journal of Immunology 2005 174 5 2533 2543 (Pubitemid 40279666)
42. Okada H., Giezeman-Smits K. M., Tahara H., Attanucci J., Fellows W. K., Lotze M. T., Chambers W. H., Bozik M. E., Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine Gene Therapy 1999 6 2 219 226 (Pubitemid 29089920)
43. Herrlinger U., Kramm C. M., Johnston K. M., Louis D. N., Finkelstein D., Reznikoff G., Dranoff G., Breakefield X. O., Yu J. S., Vaccination for experimental gliomas using GM-CSF-transduced glioma cells Cancer Gene Therapy 1997 4 6 345 352 (Pubitemid 127667126)
44. Mueller M. M., Herold-Mende C. C., Riede D., Lange M., Steiner H. H., Fusenig N. E., Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression American Journal of Pathology 1999 155 5 1557 1567
45. Nitta T., Sato K., Allegretta M., Brocke S., Lim M., Mitchell D. J., Steinman L., Expression of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor genes in human astrocytoma cell lines and glioma specimens Brain Research 1992 571 1 19 25
46. Liang Y., Diehn M., Watson N., Bollen A. W., Aldape K. D., Nicholas M. K., Lamborn K. R., Berger M. S., Botstein D., Brown P. O., Israel M. A., Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme Proceedings of the National Academy of Sciences of the United States of America 2005 102 16 5814 5819 (Pubitemid 40559642)
47. Phillips H. S., Kharbanda S., Chen R., Forrest W. F., Soriano R. H., Wu T. D., Misra A., Nigro J. M., Colman H., Soroceanu L., Williams P. M., Modrusan Z., Feuerstein B. G., Aldape K., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006 9 3 157 173 (Pubitemid 43357943)
48. Chi A. S., Wen P. Y., Inhibiting kinases in malignant gliomas Expert Opinion on Therapeutic Targets 2007 11 4 473 496 (Pubitemid 46487596)
49. Rahman R., Smith S., Rahman C., Grundy R., Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma Journal of Oncology 2010 2010 16
50. Takano S., Yamashita T., Ohneda O., Molecular therapeutic targets for glioma angiogenesis Journal of Oncology 2010 2010 11
51. Stark-Vance V., Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma Neuro-Oncology 2005 7 3 369
52. Pope W. B., Lai A., Nghiemphu P., Mischel P., Cloughesy T. F., MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 2006 66 8 1258 1260 (Pubitemid 43739717)
53. Vredenburgh J. J., Desjardins A., Herndon J. E., Marcello J., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme Journal of Clinical Oncology 2007 25 30 4722 4729 (Pubitemid 350086473)
54. Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T., Schiff D., Abrey L. E., Yung W. K. A., Paleologos N., Nicholas M. K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma Journal of Clinical Oncology 2009 27 28 4733 4740
55. Spratlin J. L., Cohen R. B., Eadens M., Gore L., Camidge D. R., Diab S., Leong S., O'Bryant C., Chow L. Q. M., Serkova N. J., Meropol N. J., Lewis N. L., Chiorean E. G., Fox F., Youssoufian H., Rowinsky E. K., Eckhardt S. G., Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G monoclonal antibody targeting the vascular endothelial growth factor receptor-2 Journal of Clinical Oncology 2010 28 5 780 787
56. Lamszus K., Laterra J., Westphal M., Rosen E. M., Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas International Journal of Developmental Neuroscience 1999 17 5-6 517 530 (Pubitemid 29421838)
57. Jun H. T., Sun J., Rex K., Radinsky R., Kendall R., Coxon A., Burgess T. L., AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts Clinical Cancer Research 2007 13 22 6735 6742 (Pubitemid 350206811)
58. Combs S. E., Heeger S., Haselmann R., Edler L., Debus J., Schulz-Ertner D., Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)phase I/II trial: study protocol BMC Cancer 2006 6, article 133
59. Diaz M. A., Rolff J., Lemm M., Fichtner I., Perez R., Montero E., Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies British Journal of Cancer 2009 100 6 950 958
60. Bode U., Buchen S., Warmuth-Metz M., Pietsch T., Bach F., Fleischhack G., Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents Journal of Clinical Oncology 2007 25 supplement 18. Proceedings of the ASCO Annual Meeting (ASCO '07)
61. Fredriksson L., Li H., Eriksson U., The PDGF family: four gene products form five dimeric isoforms Cytokine and Growth Factor Reviews 2004 15 4 197 204 (Pubitemid 38781045)
62. Cobbs C. S., Harkins L., Samanta M., Gillespie G. Y., Bharara S., King P. H., Nabors L. B., Cobbs C. G., Britt W. J., Human cytomegalovirus infection and expression in human malignant glioma Cancer Research 2002 62 12 3347 3350 (Pubitemid 34651375)
63. Soroceanu L., Akhavan A., Cobbs C. S., Platelet-derived growth factor- receptor activation is required for human cytomegalovirus infection Nature 2008 455 7211 391 395
64. Song S., Ewald A. J., Stallcup W., Werb Z., Bergers G., PDGFR + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival Nature Cell Biology 2005 7 9 870 879 (Pubitemid 41486287)
65. Reardon D. A., Akabani G., Coleman R. E., Friedman A. H., Friedman H. S., Herndon J. E., Cokgor I., McLendon R. E., Pegram C. N., Provenzale J. M., Quinn J. A., Rich J. N., Regalado L. V., Sampson J. H., Shafman T. D., Wikstrand C. J., Wong T. Z., Zhao X. G., Zalutsky M. R., Bigner D. D., Phase II trial of murine 131I -labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas Journal of Clinical Oncology 2002 20 5 1389 1397 (Pubitemid 34177447)
66. Riva P., Arista A., Tison V., Sturiale C., Franceschi G., Spinelli A., Riva N., Casi M., Moscatelli G., Frattarelli M., Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors Cancer 1994 73 1076 1082 (Pubitemid 24046672)
67. Riva P., Franceschi G., Frattarelli M., Lazzari S., Riva N., Giuliani G., Casi M., Sarti G., Guiducci G., Giorgetti G., Gentile R., Santimaria M., Jermann E., Maeke H. R., Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study Clinical Cancer Research 1999 5 10 3275s 3280s (Pubitemid 29493927)
68. Nitta T., Sato K., Yagita H., Okumura K., Ishii S., Preliminary trial of specific targeting therapy against malignant glioma Lancet 1990 335 8686 368 371 (Pubitemid 20059349)
69. Kuan C. T., Wikstrand C. J., Archer G., Beers R., Pastan I., Zalutsky M. R., Bigner D. D., Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFV International Journal of Cancer 2000 88 6 962 969
70. Kuan C. T., Reist C. J., Foulon C. F., Lorimer I. A.J., Archer G., Pegram C. N., Pastan I., Zalutsky M. R., Bigner D. D., 125 I -labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts Clinical Cancer Research 1999 5 6 1539 1549 (Pubitemid 29282963)
71. Kuan C. T., Srivastava N., McLendon R. E., Marasco W. A., Zalutsky M. R., Bigner D. D., Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas International Journal of Cancer 2010 127 3 598 611
72. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J.M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebb C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 2010 363 8 711 723
73. Fecci P. E., Sweeney A. E., Grossi P. M., Nair S. K., Learn C. A., Mitchell D. A., Cui X., Cummings T. J., Bigner D. D., Gilboa E., Sampson J. H., Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells Clinical Cancer Research 2006 12 14 4294 4305
74. Wrensch M., Wiencke J. K., Wiemels J., Miike R., Patoka J., Moghadassi M., McMillan A., Kelsey K. T., Aldape K., Lamborn K. R., Parsa A. T., Sison J. D., Prados M. D., Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival Cancer Research 2006 66 8 4531 4541
75. Wiemels J. L., Wiencke J. K., Patoka J., Moghadassi M., Chew T., McMillan A., Miike R., Barger G., Wrensch M., Reduced immunoglobulin E and allergy among adults with glioma compared with controls Cancer Research 2004 64 22 8468 8473 (Pubitemid 39491789)
76. Linos E., Raine T., Alonso A., Michaud D., Atopy and risk of brain tumors: a meta-analysis Journal of the National Cancer Institute 2007 99 20 1544 1550 (Pubitemid 351767237)
77. Rosenberg S. A., Spiess P., Lafreniere R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 1986 233 4770 1318 1321 (Pubitemid 16002234)
78. Holladay F. P., Lopez G., De M., Morantz R. A., Wood G. W., Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells Neurosurgery 1992 30 4 499 505
79. Holladay F. P., Heitz T., Chen Y. L., Chiga M., Wood G. W., Olson J. J., Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes Neurosurgery 1992 31 3 528 533
80. Plautz G. E., Touhalisky J. E., Shu S., Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells Cellular Immunology 1997 178 2 101 107 (Pubitemid 27397592)
81. Dunn G. P., Dunn I. F., Curry W. T., Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma Cancer Immunity 2007 7 12
82. Quattrocchi K. B., Miller C. H., Cush S., Bernard S. A., Dull S. T., Smith M., Gudeman S., Varia M. A., Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas Journal of Neuro-Oncology 1999 45 2 141 157 (Pubitemid 30197728)
83. Plautz G. E., Miller D. W., Barnett G. H., Stevens G. H. J., Maffett S., Kim J., Cohen P. A., Shu S., T cell adoptive immunotherapy of newly diagnosed gliomas Clinical Cancer Research 2000 6 6 2209 2218 (Pubitemid 30399186)
84. Kruse C. A., Cepeda L., Owens B., Johnson S. D., Stears J., Lillehei K. O., Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 Cancer Immunology Immunotherapy 1997 45 2 77 87 (Pubitemid 27497682)
85. Yang L., Ng K. Y., Lillehei K. O., Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma Cancer Control 2003 10 2 138 147 (Pubitemid 36437820)
86. Kruse C. A., Rubinstein D., Liau L. M., Becker D. P., Cloughsey T. F., Bigner D., Cytotoxic T lymphocytes reactive to patient major histocompatibility proteins for therapy of recurrent primary brain tumors Brain Tumor Immunotherapy 2001 New York, NY, USA Humana Press 149 170
87. Esser M. T., Dinglasan R. D., Krishnamurthy B., Gullo C. A., Graham M. B., Braciale V. L., IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8 and CD4 T lymphocyte clones Journal of Immunology 1997 158 12 5612 5618 (Pubitemid 127483963)
88. Williams N. S., Engelhard V. H., Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism Journal of Immunology 1996 156 1 153 159 (Pubitemid 26006958)
89. Giezeman-Smits K. M., Okada H., Brissette-Storkus C. S., Villa L. A., Attanucci J., Lotze M. T., Pollack I. F., Bozik M. E., Chambers W. H., Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity Cancer Research 2000 60 9 2449 2457 (Pubitemid 30262436)
90. Okada H., Attanucci J., Giezeman-Smits K. M., Brissette-Storkus C., Fellows W. K., Gambotto A., Pollack I. F., Pogue-Geile K., Lotze M. T., Bozik M. E., Chambers W. H., Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in Vivo Cancer Research 2001 61 6 2625 2631 (Pubitemid 32685848)
91. Delgado C., Hoa N., Callahan L. L., Schiltz P. M., Jahroudi R. A., Zhang J. G., Wepsic H. T., Jadus M. R., Generation of human innate immune responses towards membrane macrophage colony stimulating factor (mM-CSF) expressing U251 glioma cells within immunodeficient (NIH-nu/beige/xid) mice Cytokine 2007 38 3 165 176 (Pubitemid 47260683)
92. El Andaloussi A., Lesniak M. S., An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme Neuro-Oncology 2006 8 3 234 243 (Pubitemid 46542648)
93. Fecci P. E., Mitchell D. A., Whitesides J. F., Xie W., Friedman A. H., Archer G. E., Herndon J. E., Bigner D. D., Dranoff G., Sampson J. H., Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma Cancer Research 2006 66 6 3294 3302
94. Heimberger A. B., Abou-Ghazal M., Reina-Ortiz C., Yang D. S., Sun W., Qiao W., Hiraoka N., Fuller G. N., Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas Clinical Cancer Research 2008 14 16 5166 5172
95. Tsuji M., Komatsu N., Kawamoto S., Suzuki K., Kanagawa O., Honjo T., Hori S., Fagarasan S., Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches Science 2009 323 5920 1488 1492
96. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S., The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation International Immunology 2008 20 11 1361 1368
97. Wan Y. Y., Flavell R. A., How diverseCD4 effector T cells and their functions Journal of Molecular Cell Biology 2009 1 1 20 36
98. Wainwright D. A., Sengupta S., Han Y., Ulasov I. V., Lesniak M. S., The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human gliom PLoS ONE 2010 5 10, article e15390
99. Muranski P., Boni A., Antony P. A., Cassard L., Irvine K. R., Kaiser A., Paulos C. M., Palmer D. C., Touloukian C. E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C. S., Kerstann K. W., Feigenbaum L., Chan C. C., Restifo N. P., Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 2008 112 2 362 373
100. Kahlon K. S., Brown C., Cooper L. J. N., Raubitschek A., Forman S. J., Jensen M. C., Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells Cancer Research 2004 64 24 9160 9166 (Pubitemid 39665531)
101. Ahmed N., Salsman V. S., Kew Y., Shaffer D., Powell S., Zhang YI. J., Grossman R. G., Heslop H. E., Gottschalk S., HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors Clinical Cancer Research 2010 16 2 474 485
102. Bullain S. S., Sahin A., Szentirmai O., Sanchez C., Lin N., Baratta E., Waterman P., Weissleder R., Mulligan R. C., Carter B. S., Genetically engineered T cells to target EGFRvIII expressing glioblastoma Journal of Neuro-Oncology 2009 94 3 373 382
103. Lo A. S. Y., Ma Q., Liu D. L., Junghans R. P., Anti-GD3 chimeric sFv-CD28/T-cell receptor designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors Clinical Cancer Research 2010 16 10 2769 2780
104. Ahmed N., Ratnayake M., Savoldo B., Perlaky L., Dotti G., Wels W. S., Bhattacharjee M. B., Gilbertson R. J., Shine H. D., Weiss H. L., Rooney C. M., Heslop H. E., Gottschalk S., Regression of experimental medulloblastoma following transfer of HER2-specific T cells Cancer Research 2007 67 12 5957 5964 (Pubitemid 46985032)
105. Okada H., Tahara H., Shurin M. R., Attanucci J., Giezeman-Smits K. M., Fellows W. K., Lotze M. T., Chambers W. H., Bozik M. E., Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms International Journal of Cancer 1998 78 2 196 201 (Pubitemid 28443177)
106. Liau L. M., Black K. L., Prins R. M., Sykes S. N., DiPatre P. L., Cloughesy T. F., Becker D. P., Bronstein J. M., Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens Journal of Neurosurgery 1999 90 6 1115 1124 (Pubitemid 29241181)
107. Heimberger A. B., Crotty L. E., Archer G. E., McLendon R. E., Friedman A., Dranoff G., Bigner D. D., Sampson J. H., Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma Journal of Neuroimmunology 2000 103 1 16 25 (Pubitemid 30058249)
108. Schettini J., Mukherjee P., Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity Clinical and Developmental Immunology 2008 2008 10
109. Ardon H., De Vleeschouwer S., Van Calenbergh F., Claes L., Kramm C. M., Rutkowski S., Wolff J. E. A., Van Gool S. W., Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours Pediatric Blood and Cancer 2010 54 4 519 525
110. De Vleeschouwer S., Fieuws S., Rutkowski S., Van Calenbergh F., Van Loon J., Goffin J., Sciot R., Wilms G., Demaerel P., Warmuth-Metz M., Soerensen N., Wolff J. E. A., Wagner S., Kaempgen E., Van Gool S. W., Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme Clinical Cancer Research 2008 14 10 3098 3104
111. Liau L. M., Prins R. M., Kiertscher S. M., Odesa S. K., Kremen T. J., Giovannone A. J., Lin J.-W., Chute D. J., Mischet P. S., Cloughesy T. F., Roth M. D., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment Clinical Cancer Research 2005 11 15 5515 5525 (Pubitemid 41060828)
112. Liau L. M., Prins R. M., Kiertscher S. M., Odesa S. K., Kremen T. J., Giovannone A. J., Yang M. Y., Zetler P. M., Prins R. M., Khan-Farooqi H., Liau L. M., Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications Expert Review of Neurotherapeutics 2006 6 10 1481 1494 (Pubitemid 44690918)
113. Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Riedinger M. S., Zhang W., Prins R. M., Black K. L., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Research 2001 61 3 842 847 (Pubitemid 32175145)
114. Yu J. S., Liu G., Ying H., Yong W. H., Black K. L., Wheeler C. J., Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Research 2004 64 14 4973 4979 (Pubitemid 38924545)
115. Kim W., Liau L. M., Dendritic cell vaccines for brain tumors Neurosurgery Clinics of North America 2010 21 1 139 157
116. Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., Ohno T., Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells Cancer Immunology, Immunotherapy 2001 50 7 337 344 (Pubitemid 32835343)
117. Kikuchi T., Akasaki Y., Abe T., Fukuda T., Saotome H., Ryan J. L., Kufe D. W., Ohno T., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12 Journal of Immunotherapy 2004 27 6 452 459 (Pubitemid 39447353)
118. Schiltz P. M., Lee G. J., Zhang J. G., Hoa N., Wepsic H. T., Dillman R. O., Jadus M. R., Human allogeneic and murine xenogeneic dendritic cells are cytotoxic to human tumor cells via two distinct pathways Cancer Biotherapy and Radiopharmaceuticals 2007 22 5 672 683 (Pubitemid 350059004)
119. Schmitz M., Zhao S., Deuse Y., Schkel K., Wehner R., Whner H., Hlig K., Wienforth F., Kiessling A., Bornhuser M., Temme A., Rieger M. A., Weigle B., Bachmann M., Rieber E. P., Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity Journal of Immunology 2005 174 7 4127 4134 (Pubitemid 40395990)
120. Chan C. W., Crafton E., Fan H.-N., Flook J., Yoshimura K., Skarica M., Brockstedt D., Dubensky T. W., Stins M. F., Lanier L. L., Pardoll D. M., Housseau F., Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity Nature Medicine 2006 12 2 207 213 (Pubitemid 43214747)
121. Cheever M. A., Allison J. P., Ferris A. S., Finn O. J., Hastings B. M., Hecht T. T., Mellman I., Prindiville S. A., Viner J. L., Weiner L. M., Matrisian L. M., The prioritization of cancer antigens: a National Cancer Institute pilot
122. Weinschenk T., Schoor O., Trautwein C., Hilf N., Walter S., Singh H., Novel immunotherapy against several tumors including neuronal and brain tumors. United States Patent no. 2010/0158931 A1, 2010
123. Parajuli P., Pisarev V., Sublet J., Steffel A., Varney M., Singh R., Laface D., Talmadge J. E., Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response Cancer Research 2001 61 22 8227 8234 (Pubitemid 33091616)
124. Houbiers J. G. A., Nijman H. W., Van Der Burg S. H., Drijfhout J. W., Kenemans P., Van De Velde C. J.H., Brand A., Momburg F., Kast W. M., Melief C. J.M., In vitro induction of human cytotoxic T Iymphocyte responses against peptides of mutant and wild-type p53 European Journal of Immunology 1993 23 9 2072 2077 (Pubitemid 23265865)
125. Gnjatic S., Cai Z., Viguier M., Chouaib S., Guillet J. G., Choppin J., Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas Journal of Immunology 1998 160 1 328 333 (Pubitemid 28116746)
126. Soussi T., p53 antibodies in the sera of patients with various types of cancer: a review Cancer Research 2000 60 7 1777 1788 (Pubitemid 30207629)
127. Zhang J. G., Kruse C. A., Driggers L., Hoa N., Wisoff J., Allen J. C., Zagzag D., Newcomb E. W., Jadus M. R., Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy Journal of Neuro-Oncology 2008 88 1 65 76
128. Gomez G. G., Kruse C. A., Mechanisms of malignant glioma immune resistance and sources of immunosuppression Gene Therapy and Molecular Biology 2006 10 1 133 146 (Pubitemid 351976185)
129. Prins R. M., Cloughesy T. F., Liau L. M., Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate New England Journal of Medicine 2008 359 5 539 541
130. Mitchell D. A., Xie W., Schmittling R., Learn C., Friedman A., McLendon R. E., Sampson J. H., Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma Neuro-Oncology 2008 10 1 10 18 (Pubitemid 351250896)
131. Bao L., Dunham K., Stamer M., Mulieri K. M., Lucas K. G., Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation Biology of Blood and Marrow Transplantation 2008 14 10 1156 1162
132. Bao L., Sun Q., Lucas K. G., Rapid generation of CMV pp65-specific T cells for immunotherapy Journal of Immunotherapy 2007 30 5 557 561 (Pubitemid 46988089)
133. Parney I. F., Farr-Jones M. A., Chang L. J., Petruk K. C., Human glioma immunobiology in vitro: implications for immunogene therapy Neurosurgery 2000 46 5 1169 1178 (Pubitemid 30249948)
134. Parney I. F., Petruk K. C., Zhang C., Farr-Jones M., Sykes D. B., Chang L. J., Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model Human Gene Therapy 1997 8 9 1073 1085 (Pubitemid 27308205)
135. Zhang J. G., Eguchi J., Kruse C. A., Antigenic profiles of glioma cells to generate allogeneic vaccines or DC-based therapeutics Clinical Cancer Research 2007 13 2 566 575 (Pubitemid 46225363)
136. Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L., Royston I., Sobol R. E., Eradication of established intracranial rat gliomas by transforming growth factor antisense gene therapy Proceedings of the National Academy of Sciences of the United States of America 1996 93 7 2909 2914 (Pubitemid 26114338)
137. Mahaley M. S., Bigner D. D., Dudka L. F., Immunobiology of primary intracranial tumorspart 7: active immunization of patients with anaplastic human glioma cells: a pilot study Journal of Neurosurgery 1983 59 2 201 207 (Pubitemid 13029196)
138. Mahaley M. S. Jr., Gillespie G. Y., Gillespie R. P., Immunobiology of primary intracranial tumorspart 8: serological responses to active immunization of patients with anaplastic gliomas Journal of Neurosurgery 1983 59 2 208 216 (Pubitemid 13029197)
139. El-Shami K., Tirosh B., Bar-Ham E., Carmon L., Vadai E., Fridkin M., Feldman M., Eisenbach L., MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope European Journal of Immunology 1999 29 10 3295 3301 (Pubitemid 29484220)
140. Singh S. K., Hawkins C., Clarke I. D., Squire J. A., Bayani J., Hide T., Henkelman R. M., Cusimano M. D., Dirks P. B., Identification of human brain tumour initiating cells Nature 2004 432 7015 396 401 (Pubitemid 39551674)
141. Bao S., Wu Q., McLendon R. E., Hao Y., Shi Q., Hjelmeland A. B., Dewhirst M. W., Bigner D. D., Rich J. N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 2006 444 7120 756 760 (Pubitemid 44949604)
142. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I. R., Lu L., Irvin D., Black K. L., Yu J. S., Analysis of gene expression and chemoresistance of CD 133+ cancer stem cells in glioblastoma Molecular Cancer 2006 5, article 67
143. Hurt E. M., Farrar W. L., Farrar W. L., Purification and characterization of cancer stem cells Cancer Stem Cells 2009 Chapter 1 Cambridge University Press
144. Prestegarden L., Svendsen A., Wang J., Sleire L., Skaftnesmo K. O., Bjerkvig R., Yan T., Askland L., Persson A., Sakariassen P.., Enger P.., Glioma cell populations grouped by different cell type markers drive brain tumor growth Cancer Research 2010 70 11 4274 4279
145. Pellegatta S., Poliani P. L., Corno D., Menghi F., Ghielmetti F., Suarez-Merino B., Caldera V., Nava S., Ravanini M., Facchetti F., Bruzzone M. G., Finocchiaro G., Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas Cancer Research 2006 66 21 10247 10252 (Pubitemid 44799739)
146. Xu Q., Liu G., Yuan X., Xu M., Wang H., Ji J., Konda B., Black K. L., Yu J. S., Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens Stem Cells 2009 27 8 1734 1740
147. Bigner D. D., Pitts O. M., Wikstrand C. J., Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue Journal of Neurosurgery 1981 55 1 32 42 (Pubitemid 11125467)
148. Wei Y. Q., Wang Q. R., Zhao X., Yang LI., Tian L., Lu Y., Kang B., Lu C. J., Huang M. J., Lou Y. Y., Xiao F., He Q. M., Shu J. M., Xie X. J., Mao Y. Q., Lei S., Luo F., Zhou LI. Q., Liu C. E., Zhou H., Jiang YU., Peng F., Yuan L. P., Li Q., Wu Y., Liu JI. Y., Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine Nature Medicine 2000 6 10 1160 1166
149. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine 1995 1 1 27 31
150. Virrey J. J., Golden E. B., Sivakumar W., Wang W., Pen L., Schnthal A. H., Hofman F. M., Chen T. C., Glioma-associated endothelial cells are chemoresistant to temozolomide Journal of Neuro-Oncology 2009 95 1 13 22
151. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K. E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V., Glioblastoma stem-like cells give rise to tumour endothelium Nature 2010 468 7325 829 835
152. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E. A., Stassi G., Larocca L. M., De Maria R., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells Nature 2010 468 7325 824 830
153. Liau L. M., Black K. L., Martin N. A., Sykes S. N., Bronstein J. M., Jouben-Steele L., Mischel P. S., Belldegrun A., Cloughesy T. F., Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report Neurosurgical Focus 2000 9 6, article e8
154. Liau L. M., Salgaller M. L., Kiertscher S. M., Dendritic cell vaccine presenting eluted tumor antigens for treatment of patients with glioblastoma multiforme interim phase I trial results of DCVax[tm]-Brain Proceedings of the American Association for Cancer Research 2002 San Francisco, Calif, USA
155. Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Riedinger M. S., Zhang W., Prins R. M., Black K. L., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Research 2001 61 3 842 847 (Pubitemid 32175145)
156. Heimberger A. B., Sampson J. H., The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients Expert Opinion on Biological Therapy 2009 9 8 1087 1098
157. Heimberger A. B., Sun W., Hussain S. F., Dey M., Crutcher L., Aldape K., Gilbert M., Hassenbusch S. J., Sawaya R., Schmittling B., Archer G. E., Mitchell D. A., Bigner D. D., Sampson J. H., Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study Neuro-Oncology 2008 10 1 98 103 (Pubitemid 351250906)
158. Butowski N., Lamborn K. R., Lee B. L., Prados M. D., Cloughesy T., DeAngelis L. M., Abrey L., Fink K., Lieberman F., Mehta M., Ian Robins H., Junck L., Salazar A. M., Chang S. M., A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas Journal of Neuro-Oncology 2009 91 2 183 189
159. Bredesen D. E., Rao R. V., Mehlen P., Cell death in the nervous system Nature 2006 443 7113 796 802 (Pubitemid 44622684)
160. Hotchkiss R. S., Strasser A., McDunn J. E., Swanson P. E., Cell death New England Journal of Medicine 2009 361 16 1570 1583
161. Wyllie A. H., Kerr J. F. R., Currie A. R., Cell death: the significance of apoptosis International Review of Cytology 1980 68 251 306 (Pubitemid 11219226)
162. Cohen J. J., Apoptosis Immunology Today 1993 14 3 126 130 (Pubitemid 23068297)
163. Rock K. L., Shen L., Cross-presentation: underlying mechanisms and role in immune surveillance Immunological Reviews 2005 207 166 183 (Pubitemid 41415016)
164. Kono H., Rock K. L., How dying cells alert the immune system to danger Nature Reviews Immunology 2008 8 4 279 289 (Pubitemid 351432799)
165. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proceedings of the National Academy of Sciences of the United States of America 1993 90 8 3539 3543 (Pubitemid 23111402)
166. Witham T. F., Erff M. L., Okada H., Chambers W. H., Pollack I. F., Piepmeier J. M., Walker P., De Tribolet N., Glick R. P., Lichtor T., 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model Neurosurgery 2002 50 6 1327 1335 (Pubitemid 36322775)
167. Samaddar J. S., Gaddy V. T., Duplantier J., Thandavan S. P., Shah M., Smith M. J., Browning D., Rawson J., Smith S. B., Barrett J. T., Schoenlein P. V., A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance Molecular Cancer Therapeutics 2008 7 9 2977 2987
168. Li Y., Wang L. X., Yang G., Hao F., Urba W. J., Hu H. M., Efficient cross-presentation depends on autophagy in tumor cells Cancer Research 2008 68 17 6889 6895
169. Crotzer V. L., Blum J. S., Autophagy and its role in MHC-mediated antigen presentation Journal of Immunology 2009 182 6 3335 3341
170. Sperandio S., de Belle I., Bredesen D. E., An alternative, non-apoptotic form of programmed cell death Proceedings of the National Academy of Sciences of the Unites States of America 2000 97 26 14376 14381 (Pubitemid 32016583)
171. Yang H., Wang H., Czura C. J., Tracey K. J., The cytokine activity of HMGB1 Journal of Leukocyte Biology 2005 78 1 1 8 (Pubitemid 40979937)
172. Melcher A., Todryk S., Hardwick N., Ford M., Jacobson M., Vile R. G., Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression Nature Medicine 1998 4 5 581 587 (Pubitemid 28237357)
173. Gallucci S., Matzinger P., Danger signals: SOS to the immune system Current Opinion in Immunology 2001 13 1 114 119 (Pubitemid 32096970)
174. Rock K. L., Kono H., The inflammatory response to cell death Annual Review of Pathology 2008 3 99 126 (Pubitemid 351488277)
175. Dan Q., Sanchez R., Delgado C., Wepsic H. T., Morgan K., Chen Y., Jeffes E. W.B., Lowell C. A., Morgan T. R., Jadus M. R., Non-immunogenic murine hepatocellular carcinoma Hepa 16 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-cell immunity against the parental tumor Molecular Therapy 2001 4 5 427 437 (Pubitemid 33100280)
176. Williams C. C., Trinh H., Tran T. V., Membrane expression of macrophage colony stimulating factor on MADB106 breast cancer cells is not associated with in vitro cytotoxicity by macrophages but is associated with the induction lasting tumor immunity against syngeneic breast cancer cells in vivo Molecular Therapy 2001 3 2 216 224
177. Hoa N., Zhang J. G., Delgado C., BK channel activation results in paraptosis: a possible mechanism to explain monocyte-mediated killing of tumor cells expressing membrane macrophage colony stimulating factor Laboratory Investigation 2007 87 2 115 129
178. Hoa N., Myers M. P., Douglass T. G., Zhang J. G., Delgado C., Driggers L., Callahan L. L., VanDeusen G., Pham J. T., Bhakta N., Ge L., Jadus M. R., Molecular mechanisms of paraptosis induction: implications for a non-genetically modified tumor vaccine PLoS ONE 2009 4 2, article e4631
179. Jadus M. R., Chen Y., Boldaji M. T., Delgado C., Sanchez R., Douglass T., Al-Atar U., Schulz W., Lloyd C., Wepsic H. T., Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins Cancer Gene Therapy 2003 10 5 411 420 (Pubitemid 36528785)